EXHIBIT 400

```
1
            IN THE UNITED STATES DISTRICT COURT
             FOR THE NORTHERN DISTRICT OF OHIO
2
                      EASTERN DIVISION
3
4
    In re: NATIONAL PRESCRIPTION ) CASE NO.
                                 ) 1:17-MD-2804
    OPIATE LITIGATION
5
                                  ) Judge
    APPLIES TO ALL CASES
                           ) Dan Aaron Polster
6
       HIGHLY CONFIDENTIAL - SUBJECT TO FURTHER
                   CONFIDENTIALITY REVIEW
9
    DEPOSITION FOR PLAINTIFF
10
11
                     *** *** ***
12
13
   DEPONENT: GARY MILLIKAN
14 DATE: JANUARY 11, 2019
15
                     *** *** ***
16
17
18
19
2.0
2.1
22
23
24
25
```

1	EXAMINATION INDEX	
2	Examination by Mr. Goetz	10
	Examination by Mr. Hynes	251
3	Re-examination by Mr. Goetz	256
	Reporter's Certificate	262
4		
5	EXHIBIT INDEX	
6		
7	CVS-Millikan-2	171
	IRR, 8-30-13 CVS-MDLT1-10672-757	
8	Highly Confidential	
9	CVS-Millikan-3	196
	Email chain CVS-MDLT1-83064	
10	Confidential	
11	CVS-Millikan-4	196
	SOM Process CVS-MDLT1-83065	
12	Confidential	
13	CVS-Millikan-5	199
	Time study CVS-MDLT1-112702	
14	Confidential	
15	CVS-Millikan-6	205
	LP Analyst Time Study CVS-MDLT1-112686	
16	Confidential	
17	CVS-Millikan-7	208
	LP Analyst Time Study CVS-MDLT1-112690	
18	Confidential	
19	CVS-Millikan-9	113
	Controlled Drug-DEA SOP Manual CVS-MDLT1-8506	
20	Confidential	
21	CVS-Millikan-11	198
	Email chain CVS-MDLT1-55836	
22	Confidential Confidential	1 - 0
23	CVS-Millikan-13	159
0.4	CVS-MDLT-110268 Highly Confidential	
24		
25		

1	EXHIBIT INDEX - Continued
2	CVS-Millikan-15 155
	December 2010 PSE IRR Recap CVS-MDLT1-9740
3	Highly Confidential
4	CVS-Millikan-18
5	
6	CVS-Millikan-22
7	January 2011 Control IRR Recap CVS-MDLT1-8258 Highly Confidential
8	CVS-Millikan-33
	Track One CVS Store Information CVS-MDLT1-7362
9	Confidential
10	CVS-Millikan-36 173
	List 1 Chemicals, Policies & Procedures
11	CVS-MDLT1-25018
	Confidential
12	
13	CVS-Millikan-37
1.4	Irregular Order Logistics Communication
14	CVS-MDLT1-3348 Highly Confidential
15	Highly Confidencial
16	CVS-Millikan-38
	Email chain CVS-MDLT1-8483
17	Highly Confidential - Public Health Information
18	CVS-Millikan-45 153
	Viper PDMR Supplemental CVS-MDLT1-67863
19	Highly Confidential
20	CVS-Millikan-46
	Viper PDMR CVS-MDLT1-68377
21	Highly Confidential
22	CVS-Millikan-47 153
	Viper PDMR - High Priority CVS-MDLT1-74450
23	Highly Confidential
24	CVS-Millikan-48
	IRR, 11-30-10 CVS-MDLT1-775
25	Highly Confidential

1	EXHIBIT INDEX - Continued		
2	CVS-Millikan-10048		
	Email CVS-MDLT1-17100		
3	Highly Confidential		
4	CVS-Millikan-101 53		
	McKesson document CVS-MDLT1-15502		
5			
6	CVS-Millikan-10260		
_	Bar Graph, Opioid Analgesics Poisoning Death		
7			
8			
0	Bar Graph: U.S. Rates of Opioid Overdoes Deaths,		
9	Sales and Treatment Admissions, 1999-2010		
10	CVS-Millikan-104		
11	2012 Ohio Drug Overdose Deaths		
12	CVS-Millikan-105 66		
12	International Narcotics Control Board,		
13	Comments on Reported Statistics, 2012		
14	CVS-Millikan-106		
	Email chain, CVS-MDLT1-91508		
15	Confidential		
16	CVS-Millikan-107 89		
	CVS DEA SOP Manual CVS-MDLT1-34234		
17	Confidential		
18	CVS-Millikan-108 94		
	Controlled Drug - DEA SOP Manual CVS-MDLT1-66380		
19			
20	CVS-Millikan-109 100		
	CVS Indiana, LLC Controlled Drug, DEA SOP Manual		
21	CVS-MDLT1-89315 Confidential		
22	CVS-Millikan-111 106		
	Email CVS-MDLT1-61132		
23	Confidential		
24	CVS-Millikan-112 107		
	Email CVS-MDLT1-88956		
25	Confidential		

Case: 1:17-md-02804-DAP Doc#: 1965-82 Filed: 07/23/19 6 of 265. PageID#: 168742 Highly Confidential ty Review

1	EXHIBIT INDEX - Continued	
2	CVS-Millikan-113 109	
	CVS Distribution Center, DEA SOP Manual	
3	CVS-MDLT1-88957	
	Confidential	
4		
5	CVS-Millikan-115 21	
_	Transcript [excerpt] Nicastro	
6		
7	CVS-Millikan-117 29	
	Transcript [excerpt] Nicastro	
8		
9	CVS-Millikan-119	
	Transcript [excerpt] Nicastro	
10		
11		
12		
13		
14		
15		
17		
18		
19		
20		
21		
22		
23		
24		
25		

1 2	АРРЕ	ARANCES
3		DANIEL P. GOETZ, Esquire BRIAN ROOF, Esquire
4	Ţ	Weisman Kennedy & Berris CO LPA 1600 Midland Building
	=	101 West Prospect Street
5		Cleveland, Ohio 44115 216-781-1111
6		dgoetz@weismanlaw.com proof@weismanlaw.com
7		
8		MICHAEL ELSNER, Esquire KAITLYN EEKHOFF, Esquire
9		Motley Rice 28 Bridgeside Boulevard
10		Mount Pleasant South Carolina
11		343-216-9250 melsner@motleyrice.com
12		merbiier emocrey rrec. com
13		
	FOR THE DEFENDANT:	PAUL B. HYNES, Jr. Esquire
14		R. MILES CLARK, Esquire Zuckerman Spaeder
15		Suite 1000 1800 M Street
16		Washington, DC 20036 202-778-1800
17	I	phynes@zuckerman.com mclark@zuckerman.com
18		
19		SARAH E. HAMON, Esquire Armstrong Teasdale
20	\$	Suite 1800 7700 Forsyth Boulevard
21	S	St. Louis, Missouri 63105
22		314-552-6672 sharmon@ArmstrongTeasdale.com
23		onar monear macrony reasonate. Com
24		
25		

1	APPEARANCES - Continued	
2		
3	FOR THE DEFENDANT:	SCOTT D. QUELLHORST, Esquire
	Walmart	Jones Day
4	via speakerphone	77 West Wacker Street
		Chicago, Illinois
5		312-269-4251
		squellhorst@jonesday.com
6		
7	FOR THE DEFENDANT:	CHRISTIAN W. SAUCEDO, Esquire
	AmerisourceBergen	Reed Smith
8	via speakerphone	Three Logan Square
		Suite 3100
9		1717 Arch Street
		Philadelphia, PA 19103
10		215-851-8204
		csaucedo@reedsmith.com
11		
12	FOR THE DEFENDANT:	EMILY DILLINGHAM, Esquire
	Endo entities	Arnold & Porter
13	Par entities	250 West 55th Street
	via speakerphone	New York, New York 10019
14		212-836-7408
	emily	.dillingham@arnoldporter.com
15		
16		
17		
	ALSO PRESENT: Ben	Stanson, videographer
18		Jon Knowles, trial technologist
19		
20		
21		
22		
23		
24		
25		

The deposition of GARY MILLIKAN, taken on 1 2. discovery, pursuant to Notice heretofore filed, in the Latitude Room, 2nd Floor, of Le Meridien Indianapolis, 3 4 123 South Illinois Street, Indianapolis, Indiana, on 5 January 11, 2019, at approximately 8:59 a.m.; upon oral examination, and to be used in accordance with 6 the Federal Rules of Civil Procedures. 7 8 9 10 11 THE VIDEOGRAPHER: We are now on the record. 12 My name is Ben Stanson. I'm the videographer for 13 Golkow Litigation Services. Today's date is 14 January 11, 2019, and the time is 8:59 a.m. 15 This video deposition is being held in 16 Indianapolis, Indiana, in the matter of National 17 Prescription Opiate Litigation, MDL Number 2804, 18 pending in the U.S. District Court, Northern District 19 of Ohio, Eastern Division. 20 The deponent is Gary Millikan. 21 Will counsel please identify yourselves for 22 the record? 23 MR. ROOF: Brian Roof, for Plaintiff, law firm of Weisman Kennedy and Berris. 24 25 MR. GOETZ: Dan Goetz, on behalf of

Plaintiff. 1 MS. HARMON: Sarah Harmon for Cardinal 2. Health. 3 MR. CLARK: Miles Clark, Zuckerman and 4 5 Spaeder, on behalf of CVS Indiana, LLC; CVS Rx Services, Inc., and the witness. 6 7 MR. HYNES: Paul Hynes, Zuckerman and 8 Spaeder, on behalf of the same parties. 9 THE VIDEOGRAPHER: Would counsel on the phone 10 please identify yourselves for the record? 11 MS. DILLINGHAM: Hi. Emily -- go ahead. 12 MR. ELSNER: Michael Elser, from Motley Rice, 13 on behalf of the Plaintiffs. 14 MS. DILLINGHAM: Emily Dillingham, Arnold Porter, on behalf of the Endo and Par Defendants. 15 16 MR. SAUCEDO: Christian Saucedo, from Reed 17 Smith, on behalf of AmerisourceBergen. 18 THE VIDEOGRAPHER: Thank you. Our court 19 reporter is Kim Keene. 20 Will you please swear in the witness? 21 22 23 24

25

```
1
 2.
              GARY MILLIKAN, after having first been duly
     administered an oath, testified as follows:
 3
 4
              THE WITNESS: I do.
 5
              THE REPORTER: Thank you.
 6
 7
 8
                          EXAMINATION
    BY MR. ROOF:
          Q. Good morning, Mr. Millikan.
10
11
            Good morning.
         Α.
12
          Q. We met off the record. My name is Brian
13
    Roof, and as I said earlier, I represent the
    Plaintiffs.
14
15
              Can you state your full name for the record
16
    and spell it?
17
             My name is Gary Lee Millikan. G-A-R-Y,
18
    L-E-E, M-I-L-I-K-A-N.
            And where do you currently live?
19
          Ο.
20
         A. I live at Indianapolis, Indiana.
         Q. What's the address?
21
22
         A. 10944 Echo Trail, 46236.
23
          Q. And what's your highest level of education
    that you've achieved?
24
```

I have a bachelor of science.

25

- 1 O. And what was that in?
- 2 A. It was in pharmacy.
- Q. Pharmacy?
- 4 And from what institute did you get that
- 5 degree from?
- A. I graduated from Purdue University.
- 7 Q. Do you have any post degrees? Graduate
- 8 degrees?
- 9 A. No, sir.
- 10 Q. Are you a pharmacist?
- 11 A. Yes, I am a pharmacist.
- 12 Q. Do you have any other certifications or
- anything like that, besides your degree from Purdue
- 14 University?
- A. No, I don't believe so.
- Q. No certifications in DEA regulations or
- 17 anything like that?
- MR. HYNES: Objection to form.
- 19 THE WITNESS: No, I don't believe so.
- Q. When were you first hired by the Indianapolis
- 21 distribution center?
- MR. HYNES: Objection to form.
- 23 THE WITNESS: The -- I was first hired into
- 24 the distribution center in 1995.
- Q. And were you hired by CVS Indiana LLC or CVS

- 1 Pharmacy, Inc?
- 2 A. This is prior to CVS. I began my career with
- 3 Hook drugs, which was purchased by Revco, and in 1995,
- 4 I went into the distribution center.
- 5 Q. And in 1995, who was your employer?
- A. Revco.
- 7 Q. And then when did you work for Hook?
- 8 A. I worked for Hook's from 1977 until the Revco
- 9 acquisition.
- 10 Q. Do you know when that occurred?
- 11 A. In 1995.
- Q. And then in 1995, when you worked for Revco,
- 13 you went to the Indianapolis distribution center?
- 14 A. Yes, I did.
- Q. And where were you before that?
- 16 A. I was in the Hook corporate office.
- Q. And what did -- was your position in 1995
- 18 with Revco?
- 19 A. I was a pharmacy manager for distribution.
- Q. And how long did you hold that role for?
- 21 A. Until 1998.
- Q. And what happened in 1998?
- A. After CVS purchased Revco, I was promoted
- 24 from pharmacy manager to operations manager for the
- 25 entire facility.

- Q. So when CVS purchased Revco in 1998, you were
- promoted to operations manager?
- A. Shortly after the purchase. I don't remember
- 4 the exact time frame, but it wasn't long. It was a
- 5 few months.
- 6 Q. So, the year was 1998?
- 7 A. Yes.
- 8 Q. And then what was your next position after
- 9 operations manager?
- 10 A. I held the position of operations manager
- until probably 2009 or '10, and they changed my title
- to production manager because a decision had been made
- that each facility would only have one operations
- 14 manager.
- O. And so, was that a demotion?
- MR. HYNES: Objection to form.
- 17 THE WITNESS: I don't -- my role did not
- 18 change. My title changed.
- 19 Q. And there was another operations manager,
- 20 though?
- 21 A. Before that, there was a senior operations
- 22 manager, and his title was changed to operations
- 23 manager.
- O. And who was that?
- 25 A. Andy Koropoulis.

- Q. And then your title was changed from
- 2 operations manager to production manager?
- A. Yes, it was.
- Q. But your role did not change?
- 5 A. No, it did not.
- 6 Q. Your duties did not change?
- 7 A. No, they did not.
- Q. And then from 2009/2010, how long did you
- 9 hold the production manager?
- 10 A. Until June of 2012, when I retired from the
- 11 company.
- Q. Going back to your operations manager
- position from 1998 to 2009 or 2010, what were your
- 14 duties?
- 15 A. The facility is 1 million square feet,
- 16 approximately 6- to 900 employees, five days a week,
- 17 three shift operation. I had various duties over that
- time period, over different departments, whether it be
- 19 shipping, order filling, inventory control,
- 20 receiving.
- Q. Anything else?
- 22 A. And pharmacy at times. I -- I believe I had
- responsibilities for everything in the facility at
- 24 some time during that time period.
- Q. When you say you had responsibilities for

- 1 everything at some point, was that on a continuous
- basis or is that at separate points?
- A. At separate points. Throughout that time
- 4 period, CVS was acquiring other companies. There were
- 5 many times when the director, the senior ops manager,
- 6 and the HR manager were out of the building for a
- 7 significant period of time and I was the senior person
- 8 in the building.
- 9 Q. As operations manager, did you report
- 10 directly to Mark Nicastro?
- MR. HYNES: Objection. Time period.
- MR. ROOF: As operations manager.
- 13 THE WITNESS: I -- as operations manager
- 14 during that period --
- 15 O. Yes.
- 16 A. -- '98 to '09, he was only there for the
- 17 period of '08 and '09, and I believe I reported
- 18 directly to him during that time, although it is
- 19 possible that I reported to the senior ops manager
- 20 part of that time. There's a few different org
- 21 charts.
- 22 O. I noticed that.
- 23 And who's the senior ops manager again?
- 24 A. Andy Koropoulis.
- Q. Okay. So, it's your testimony that Mark

- 1 Nicastro was only director from '08 to '09?
- A. No. He came in the building in '08. I
- 3 thought we were talking about the time period up to
- 4 '09. He is still the director of the facility.
- 5 Q. And prior to his -- well, strike that.
- 6 When did he arrive at the Indianapolis DC?
- 7 A. He arrived in July of 2008.
- Q. So from the -- the period that you were
- 9 operations manager, from '08 to approximately 2010,
- 10 Mark Nicastro was the director of the Indianapolis DC?
- MR. HYNES: Objection. Mischaracterizes the
- 12 testimony.
- THE WITNESS: Yes, he was.
- Q. And who was the director of the Indianapolis
- 15 DC prior to that?
- A. Prior to Mark Nicastro, it was Dana Lilly.
- Q. And how long did Dana Lilly have the position
- 18 of director?
- 19 A. I don't remember when he came in. Early
- 20 2000s until 2008, when he was promoted.
- Q. And who was the director prior to Dana
- 22 Lilly?
- A. That was Gary Kanapka.
- Q. And when was he the director of the
- 25 Indianapolis DC?

- 1 A. I don't remember exactly, but it would be '98
- 2 or '99 until early 2000s.
- Q. And when you were production manager from
- 4 1998 through 2009, 2010, who did you report to?
- 5 A. I was not production manager during that time
- 6 period. I was pharmacy manager and then operations
- 7 manager.
- 8 Q. You were pharmacy manager when?
- 9 A. 1995 to 1998.
- 10 Q. And then from 1998 through 2010, you were --
- 11 A. From 1998 until about 2009 or '10, I was the
- 12 operations manager.
- Q. Okay. And then from about 2009 or 2010
- 14 through June of 2012, when you retired, you were the
- 15 production manager?
- 16 A. Yes, I was.
- Q. Okay. Who did you report to as the
- 18 production manager?
- 19 A. It was probably Mark Nicastro, the director,
- 20 for that entire time. It's possible that it was
- 21 through Andy Koropoulis, the operations manager.
- Q. Why do you say it's possible?
- 23 A. I -- I don't remember the organization charts
- 24 as -- during that period.
- Q. Who did your reviews during the time you were

- 1 production manager?
- 2 A. Again, I -- I'm not completely sure. I
- 3 believe it's the director, Mark Nicastro. It is
- 4 possible that it was the operations manager, Andy
- 5 Koropoulis.
- 6 Q. And that same is true when you were
- 7 operations manager, correct?
- 8 A. Yes, it is.
- 9 Q. Okay. And when you were operations manager,
- were you employed by CVS Pharmacy, Inc., or CVS
- 11 Indiana, LLC?
- 12 A. My W2 says: CVS Indiana, LLC.
- Q. And that was the entire time you were
- 14 employed by a CVS entity?
- 15 A. I'm not -- I'm not sure.
- Q. But the time you were operations manager and
- 17 production manager, you were employed by CVS Indiana,
- 18 LLC?
- 19 MR. HYNES: Objection. Mischaracterizes his
- 20 testimony.
- THE WITNESS: I'm not sure how long that
- 22 title -- that company was in place without going back
- and looking at all of those W2s.
- Q. So when you were an operations manager,
- though, you were a CVS Indiana, LLC employee?

- 1 MR. HYNES: Same objection.
- THE WITNESS: I believe that CVS Indiana, LLC
- 3 was specifically my company.
- Q. We're going to talk about suspicious order
- 5 monitoring and diversion, and I just want to make sure
- 6 we're on the same page as to what those terms mean.
- 7 And the way I define suspicious order
- 8 monitoring is the monitoring of orders that are
- 9 unusual size, orders that deviate substantially from a
- 10 normal pattern, and orders that are of unusual
- 11 frequency.
- Do you understand that?
- 13 A. The suspicious orders that we had to
- 14 determine would meet that criteria.
- Q. Okay. And diversion would be diverting
- 16 controlled substances to an illegitimate channel
- 17 rather than distributing it to medical, scientific, or
- 18 industrial channels?
- MR. HYNES: Objection to form.
- THE WITNESS: The -- my role in diversion
- 21 when I was directly -- part of it was to ensure that
- the drugs that we shipped went to legitimate
- 23 pharmacies for legitimate concerns.
- Q. So, can we have an understanding, though,
- 25 that diversion means diverting of controlled

- 1 substances to illegitimate channels?
- 2 MR. HYNES: Objection to form.
- THE WITNESS: I have -- my role, when I was
- 4 directly involved with the suspicious ordering, was to
- 5 make sure that what we shipped was legitimate, to a
- 6 legitimate store for a legitimate reason.
- 7 Q. We'll use that as you -- the definition of
- 8 diversion then, okay?
- 9 A. Okay.
- 10 Q. And hydrocodone is a controlled substance?
- 11 A. Yes, it is.
- 12 Q. And hydrocodone combination products are a
- 13 controlled substance?
- 14 A. Yes, they are.
- Q. And another name for hydrocodone combination
- 16 products is HCPs?
- 17 A. I'm not sure that I'm aware of that --
- Q. You never --
- 19 A. -- term.
- Q. You never heard of the term "HCPs" before?
- 21 A. HCP?
- 22 Q. Yes.
- A. No, I don't believe I have.
- Q. Okay. As operations manager and production
- 25 manager, did you oversee the pharmacy?

- 1 A. There were times when I did oversee the
- 2 pharmacy. There were some parts of the time when I
- 3 did not.
- 4 Q. Can you tell me those dates?
- A. I don't know for sure, but I believe from
- 6 about 2009 till my retirement in June of 2012, I did
- 7 not have direct responsibility for pharmacy.
- Prior to that, from '98 to '08, while I'm not
- 9 completely sure that I always had it, I feel like I
- 10 probably did.
- Q. Why do you say "probably"?
- 12 A. I feel pretty certain that I did. I just
- don't remember.
- Q. And why from 2009 through 2012 did you not
- 15 have direct oversight of the pharmacy?
- 16 A. The director of the facility redid the
- 17 responsibilities for Andy Koropoulis and myself, and
- 18 he gave him the direct responsibility for pharmacy.
- 19 Q. And that was Mark Nicastro?
- 20 A. Yes, it was.
- 21 (CVS-Millikan-115 was marked for
- 22 identification.)
- Q. And I want to hand you what is marked as
- 24 Exhibit 115.
- MS. DILLINGHAM: Could you read the Bates

- 1 number for that document?
- MR. ROOF: It's deposition testimony of Mark
- 3 Nicastro.
- 4 Q. Like I said, Exhibit 115, his deposition
- 5 transcript -- partial deposition transcript of Mark
- 6 Nicastro. The first page is the cover page for the
- 7 deposition transcript of the video deposition of Mark
- 8 Nicastro dated December 6, 2018 in Indianapolis,
- 9 Indiana.
- Do you see that on the first page,
- 11 Mr. Millikan?
- 12 A. I'm sorry. Repeat the question.
- Q. First page is a cover page for the video
- deposition of Mark Nicastro dated December 6, 2018 in
- 15 Indianapolis, Indiana.
- Do you see that?
- 17 A. Yes.
- Q. Okay. And then the second page is page 23?
- 19 A. Yes. Yes.
- Q. And the question on line 15 says:
- "When you joined in 2008, who was responsible
- for pharmacy related aspects of the business in
- 23 Indianapolis?
- 24 Answer: "Gary Millikan was my operations
- 25 manager and he oversaw the pharmacy."

- 1 Did I read that correctly?
- 2 A. Yes.
- Q. Is that a correct statement?
- 4 A. I -- I was indirectly responsible. There was
- 5 a pharmacy manager, I believe.
- 6 Q. So, Mark Nicastro is not directly correct in
- 7 his testimony here?
- 8 MR. HYNES: Object to the form.
- 9 Mischaracterizes the document.
- 10 THE WITNESS: I'm not sure how he meant that
- on "responsible."
- Q. But you're saying you're now indirectly
- 13 responsible for the pharmacy, correct?
- 14 A. In 2008, I -- in 2008, pharmacy fell under
- me, but there were other people that I managed that
- 16 directly were involved with pharmacy.
- Q. And who were those people?
- 18 A. While I -- I'm not sure on that date. It was
- 19 either Steve Campbell or Gary Lamberth as the pharmacy
- 20 manager, and there would have been a pharmacy
- 21 supervisor or two.
- Q. So there was a pharmacy manager under you,
- 23 correct?
- 24 A. Yes.
- Q. And then the pharmacy supervisor under you?

- 1 A. Yes. And then there would have been another
- 2 pharmacy supervisor on the other shift.
- Q. So two pharmacy supervisors under you?
- 4 A. Yes. Well, the second shift one did not
- 5 directly report to me. They reported through a second
- 6 shift manager.
- 7 Q. So the only two direct reports was the
- 8 pharmacy manager and the pharmacy supervisor,
- 9 correct?
- 10 A. My -- one of my direct reports would have
- 11 been the pharmacy manager. The pharmacy supervisor
- would have reported to the pharmacy manager.
- Q. And then under the pharmacy supervisor were
- 14 the pickers and packers?
- 15 A. They would have had all of the warehouse
- 16 associates: receiving, picking orders, shipping
- 17 orders, returns.
- Q. And that's what is called the pickers and
- 19 packers?
- MR. HYNES: Objection to form.
- THE WITNESS: That's a term that is used. I
- 22 prefer warehouse associates.
- Q. Okay. We can use warehouse associates.
- So indirectly, the warehouse associates
- reported through you, correct?

- 1 A. Yes, they did.
- Q. What were your duties regarding suspicious
- order monitoring of controlled substances and
- 4 diversion?
- 5 MR. HYNES: Objection. Time period.
- Q. While you were operations manager.
- 7 A. While I was operations manager from 1998 till
- 8 2009 or '10, I had indirect knowledge and oversight
- 9 over the Suspicious Order Monitoring program.
- 10 Q. When you said you had indirect oversight over
- 11 the SOM, what do you mean?
- 12 A. I mean that the pharmacy manager, supervisor,
- admin. personnel, and the warehouse associates in the
- 14 controlled substance area were actually doing the
- 15 program.
- Q. And so what was your role as indirect
- 17 oversight over SOM?
- 18 A. Just the fact that that reported up through
- 19 me. Again, it was a million square feet, the number
- of associates. It was one of my responsibilities.
- Q. So the people that reported to you, or up
- 22 through you actually did the work for SOM, and -- but
- since you were over them or managed them, you had
- indirect oversight of SOM; is that correct?
- 25 A. Yes.

- 1 Q. Anything else you did regarding suspicious
- order monitoring or diversion?
- MR. HYNES: Objection. Time period.
- 4 Q. Same time period.
- 5 A. The same time period?
- No.
- 7 Q. And what about your duties regarding
- 8 suspicious order monitoring of controlled substances
- 9 and diversion when you were production manager?
- 10 MR. HYNES: Objection. Compound.
- Go ahead.
- 12 A. When I was production manager, Andy
- 13 Koropoulis had responsibility of pharmacy, but because
- of my background in pharmacy, I had -- some knowledge
- of the process and I continued to work with the DEA on
- 16 the audits and --
- 17 Q. Besides working with the DEA and audits,
- 18 anything else?
- 19 A. I don't believe so.
- Q. Did you work with the DEA on audits when you
- 21 were operations manager?
- 22 A. Yes, I did.
- Q. And what do you mean by you worked with the
- 24 DEA on audits?
- A. When the DEA came to the facility to do their

- 1 annual -- not annual, but do an audit, I was one of
- 2 the persons who was with them.
- Q. And what do you mean by one of the persons
- 4 with them?
- 5 A. They had my name, I believe, on the document
- 6 when they came to the facility.
- 7 Q. On what document?
- 8 A. I don't remember what that's called.
- Q. And so what did you do during these audits?
- 10 A. Oh, the information that they requested,
- 11 balancing of the inventory, answering any questions.
- 12 Q. So you provided the information requested,
- 13 you balanced the inventory, and you answered
- 14 questions.
- 15 Anything else during the audit?
- A. No, not that I recall.





```
1
2
3
4
5
6
```


- 7 Q. Okay. Who else was involved in the DEA
- 8 audits?
- 9 A. Normally, it was two inspectors.
- 10 Q. And those two inspectors were from the DEA,
- 11 correct?
- 12 A. Yes.
- Q. And who was involved from CVS Indiana?
- 14 A. The loss -- someone from loss prevention.
- 15 And then if they wanted to talk to someone, warehouse
- 16 associate or --
- Q. So it was just you and the loss prevention
- 18 person handling the DEA audits?
- 19 A. As best I can remember.
- Q. And who took the lead on the DEA audits, you
- 21 or the loss prevention?
- MR. HYNES: Object to the form.
- A. I believe we had shared responsibility.
- Q. And again, your responsibility was providing
- the information requested, balancing, and then


- 1 answering questions?
- 2 A. Yes.
- Q. And that was balancing what again?
- 4 A. The inventory of a selected controlled
- 5 substances.
- 6 Q. And you had no other responsibilities during
- 7 the DEA audit?
- 8 A. Not that I can recall at this time. I'm --
- 9 Q. As either operations manager or production
- 10 manager, were you responsible for implementing the
- 11 standard operating procedure for controlled drugs?
- MR. HYNES: Objection to form.
- 13 A. Could you repeat that?
- Q. As either -- well, let's start with as
- operations manager. Were you responsible for
- 16 implementing the standard operating procedures for
- 17 controlled drugs?
- MR. HYNES: Objection to form.
- 19 A. The -- no, I was not.
- 20 (CVS-Millikan-117 was marked for
- 21 identification.)
- Q. I'm going to go to Exhibit 117, which is
- 23 another partial deposition transcript.
- MR. HYNES: Thanks, Brian.
- Q. Again, first page of Exhibit 117 is the cover

```
page for the video deposition of Mark Nicastro on
 1
     December 6, 2018, correct?
 3
          Α.
              Yes.
          Q. And then the next page is page 46 of
 4
    Mr. Nicastro's deposition, correct?
 5
 6
          A.
              Yes.
 7
 8
 9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
```













- 1 MR. HYNES: Objection.
- 2 A. While I don't remember the exact dates in
- 3 that whole time period, there was a time period when
- 4 he had responsibility for pharmacy.
- 5 Q. So sometime when you were production manager,
- 6 he had responsibility for pharmacy?
- 7 A. I believe so.
- 8 Q. And did you have responsibility for pharmacy
- 9 at any time when you were production manager?
- 10 A. I don't remember.
- 11 Q. Then in January of 2002, you started as a
- 12 part-time employee with CVS Indiana, LLC?
- MR. HYNES: Did you say 2002?
- 14 A. No.
- 15 MR. GOETZ: 2013. January of 2013.
- MR. HYNES: Could you repeat the question.
- 17 2002.
- MR. ROOF: Yeah, sure.
- 19 BY MR. ROOF:
- Q. Then in January of 2013, you started as a
- 21 part-time employee for CVS Indiana, LLC?
- 22 A. I believe it was actually in November of
- 23 2012.
- 24 (CVS-Millikan-18 was marked for
- 25 identification.)


```
Ο.
              I want to hand you what has been marked as
 1
    Exhibit 18. Maybe we can just refresh your
     recollection here.
 3
 4
          Α.
             Okay.
 5
          Q.
              This is your personnel file.
              For the people on the phone, this document
 6
 7
    was produced by CVS in the past couple of days.
 8
     There's no Bates number on it, and --
              MR. HYNES: We can do a Bates number if you
 9
10
     want.
11
              MR. GOETZ: It doesn't matter.
12
              MR. HYNES: Okay.
13
     BY MR. ROOF:
14
15
16
17
18
19
20
21
22
23
24
25
```













































- 1 or crisis?
- MR. HYNES: Same objection.
- A. I'm aware that various things are reported.
- 4 I'm not privy to all of the facts of it.
- Q. What about in 2007? Were you aware about the
- 6 opioid crisis in 2007?
- 7 MR. HYNES: Same objection.
- 8 A. I don't recall.
- 9 O. And what about between 2008 and 2012?
- MR. HYNES: Same objection.
- 11 A. I don't recall.
- 12 Q. Did you know that hydrocodone and hydrocodone
- combination products were at the center of the opioid
- 14 crisis?
- MR. HYNES: Same objection.
- 16 A. No.
- Q. Did you know that the Indianapolis DC had a
- 18 role to play in preventing this epidemic?
- MR. HYNES: Same objection.
- 20 A. CVS distribution center has a role to ship
- 21 legitimate prescription needs to our legitimate stores
- 22 for legitimate patients.
- Q. And to prevent diversion, correct?
- MR. HYNES: Same objection.
- A. We want to make sure that those products go


```
in the correct channels.
 1
              (CVS-Millikan-101 was marked for
     identification.)
 3
          Q. Handing you what has been marked as Exhibit
 5
    101.
              Exhibit 101 is Bates stamped 15502 through
 6
 7
    15526.
              Do you see that in the lower right-hand
 8
    corner?
10
         A. Yes.
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
```














```
1
 2.
 3
 4
 5
 6
 7
              (CVS-Millikan-102 was marked for
     identification.)
 8
              I'm going to hand you what has been marked as
 9
     Exhibit 102.
10
11
              102 is not Bates stamped. Exhibit 102 is
12
    called, "Poisoning Deaths, Opioid Analgesics,"
13
    correct?
14
         A. Yes.
15
            And it is a bar graph, correct?
          Q.
16
         A. Yes.
17
          Q. And it is a bar graph showing poisoning
18
    deaths from opioid analgesics, correct?
              MR. HYNES: Objection to form.
19
20
            That's what is says.
         Α.
21
          Q. Okay. And it is from 1999 through 2013?
22
         Α.
            Yes.
23
            And there is a steady increase in deaths from
    1999 to 2013, correct?
24
25
              MR. HYNES: Objection to form.
```

- 1 A. That's what it shows.
- Q. And in 1999 there was 4,041 deaths from
- 3 opioid analgesics, correct?
- 4 MR. HYNES: Objection to form.
- 5 A. That is what it alleges.
- 6 Q. And then it peaks out in 2011 at 16,917,
- 7 correct?
- 8 MR. HYNES: Same objection.
- A. Again, that's what it alleges.
- 10 Q. And then it tapers off at -- in 2013 at
- 11 16,200, correct?
- MR. HYNES: Same objection.
- 13 A. Again, that is what it alleges.
- Q. Yeah. And the source of this is the
- 15 CDC/NCHS, National Vital Statistics System --
- MR. HYNES: Same objection.
- 17 Q. -- correct?
- 18 A. Yes.
- 19 Q. And the U.S. Drug Enforcement Administration,
- 20 Office of Diversion Control published this document?
- MR. HYNES: Same objection.
- 22 A. I'm not sure.
- 23 Q. It says --
- A. I see where it says that, but I don't see
- where it says it published it, but...

- Q. But do you see where it says U.S Drug
- 2 Enforcement Administration, Office of Diversion
- 3 Control in the lower right-hand corner?
- 4 A. Yes.
- 5 Q. Did you know about the information conveyed
- 6 in Exhibit 102?
- 7 MR. HYNES: Objection to form.
- 8 A. I don't believe so.
- 9 (CVS-Millikan-103 was marked for
- 10 identification.)
- 11 Q. Handing you what has been marked as Exhibit
- 12 103.
- And this is the document that you referred to
- 14 earlier and said you reviewed with your attorneys in
- preparation for this deposition, correct?
- MR. HYNES: Objection. Don't answer the
- 17 question.
- Q. He already answered the question. Go ahead
- 19 and answer it.
- MR. HYNES: Don't answer it.
- Q. Have you seen this document before?
- MR. HYNES: Objection. Instruct the witness
- 23 not to divulge anything that happened during prep
- 24 session.
- Q. Have you seen this document before?

```
I guess I can't answer.
 1
          Α.
          Q. So, that's a yes?
              MR. HYNES: Objection. Asked and answered.
 3
          Q. We are relying on your earlier testimony
 4
 5
    then.
 6
 7
 8
 9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
```


```
1
 2.
 3
 4
 5
 6
 7
              (CVS-Millikan-104 was marked for
     identification.)
 8
              Handing you what has been marked as Exhibit
10
     104. Again, this document is not Bates stamped.
              Exhibit 104 is dated 2012, Ohio Drug Overdose
11
12
    Deaths, correct?
13
         Α.
            Yes.
14
          Q. Have you seen this document before?
15
              MR. HYNES: Objection, to the extent this
16
    calls for the witness to divulge what he reviewed
17
    during prep.
18
            Have you seen this document before?
19
            I don't believe so.
20
          Q. The first sentence says, "Drug overdose
    deaths continue to be a public health crisis in Ohio
21
22
    with 366 percent increase in the number of deaths from
23
    2000 to 2012."
24
              And then it cites to see Figure 1, correct?
25
          Α.
            Yes.
```


- 1 Q. I read that correctly?
- 2 A. Yes.
- Q. And the source for that is the Ohio
- 4 Department of Health, correct?
- 5 MR. HYNES: Objection to form.
- 6 A. Yes.
- 7 Q. The first bullet point says, "Unintentional
- 8 drug overdoses caused 1,914 deaths to Ohio residents
- 9 based on data in 2012. This is the highest number of
- 10 deaths on record for drug overdose, and surpasses the
- 11 previous highest number (1,765) in 2011, by 8.4
- 12 percent."
- Did I read that correctly?
- 14 A. Yes.
- Q. And then the next bullet point says, "In
- 16 2012, five Ohioans died every day from unintentional
- drug overdose, or one every five hours," correct?
- MR. HYNES: Objection to form.
- 19 A. That's what it says.
- Q. And the next bullet point says,
- "Unintentional drug overdose continues to be the
- leading cause of injury related deaths in Ohio, ahead
- of motor vehicle traffic crashes, suicide and falls.
- 24 This trend began in 2007 and continues through 2012."
- Did I read that correctly?

- 1 A. Yes.
- Q. And then the next sentence says, "Opioids
- 3 (prescription or heroin) remain the driving factor
- 4 behind the unintentional drug overdose epidemic in
- Ohio. Approximately two-thirds (1,272; 66.5 percent)
- of the drug overdoses involved any opioid in 2012,
- 7 similar to 2011 (1,154; 65 percent)."
- 8 Did I read that correctly?
- 9 A. Yes.
- 10 Q. Did you know about the information conveyed
- 11 in Exhibit 104?
- MR. HYNES: Objection. Time period.
- Q. Before today.
- 14 A. I'm not sure.
- 15 O. You have no idea?
- 16 A. I'm not sure if I knew or not.
- Q. Did anybody from CVS tell you about the
- information conveyed in Exhibit 104?
- 19 A. I'm not sure if they have or not.
- 20 (CVS-Millikan-105 was marked for
- 21 identification.)
- Q. Handing you what has been marked as
- 23 Exhibit 105. This is also not Bates stamped.
- Exhibit 105 is titled, International
- 25 Narcotics Control Board Comments on Reported

- 1 Statistics on Narcotic Drugs-2012, correct?
- 2 A. Yes.
- Q. Have you seen Exhibit 105 before?
- 4 MR. HYNES: Objection and instruct the client
- 5 not to answer with respect to what he reviewed during
- 6 prep.
- 7 He can answer with respect to whether he's
- 8 reviewed this document outside of his prep session.
- 9 Go ahead.
- 10 A. I don't believe so.
- Q. The first entry says: U.S. was the country
- 12 with the highest consumption of hydrocodone
- 13 (approximately 45.5 tons, or 99 percent, of global
- 14 consumption).
- Did I read that correctly?
- 16 A. Yes.
- Q. Were you aware of this?
- 18 A. No.
- 19 Q. After reviewing Exhibits 101 through 105,
- does this change your opinion that there was an opioid
- 21 epidemic between 2006 and 2013 in the United States?
- MR. HYNES: Objection to form.
- A. No, I can't comment on that wording based on
- these documents without looking into it more.
- Q. If you had known the information in

- 1 Exhibits 101 through 105, and that there was an opioid
- 2 crisis in the U.S., would you have done your job
- 3 differently?
- 4 MR. HYNES: Objection to form. Lack of
- 5 foundation.
- A. No. We had a duty to make sure that
- 7 legitimate prescriptions went to legitimate stores for
- 8 legitimate patients. So despite anything, we would
- 9 make sure that we were following the correct.








- 1 Exhibit 106.
- 2 106 is Bates stamped 91508 through 91518,
- 3 correct?
- 4 A. Yes.
- 5 Q. Have you seen Exhibit 106 before?
- 6 MR. HYNES: Objection to the extent it calls
- 7 for the client, the witness, to divulge documents
- 8 reviewed during prep. I instruct the witness to only
- 9 answer as to what he's reviewed outside of his prep
- 10 session.
- MR. GOETZ: What is the grounds for that? I
- 12 mean, is -- is there a -- are you referencing a case
- management order? I'm curious.
- MR. HYNES: No, no. I just -- I don't
- 15 think -- what we discussed during his prep session, I
- 16 think that's privileged.
- MR. GOETZ: You're not asking what you
- 18 discussed. You're asking if he saw that document.
- 19 MR. HYNES: But I think documents I choose to
- 20 show him, I think that's privileged.
- MR. GOETZ: We're not asking him: What
- documents did the lawyer choose to show you?
- MR. HYNES: He's asking --
- 24 MR. GOETZ: Asking: Did you see this
- 25 document? It's a different question than,


- 1 Mr. Millikan, what documents did Mr. Hynes choose to
- 2 show you during the prep?
- MR. HYNES: But -- but if the answer is, I
- 4 saw this during prep --
- 5 MR. GOETZ: Totally different question.
- 6 MR. HYNES: But if his answer is, I saw this
- 7 during prep, that's, to me, privileged.
- 8 Do you agree?
- 9 MR. GOETZ: Those are the documents -- no, I
- don't because those are the documents we chose to use.
- It's a different question than, what
- documents did Mr. Hynes show you?
- If we have a document that we choose to use,
- 14 we have a right to know if he saw them before he
- 15 walked in here.
- MR. ROOF: And Eric allowed that yesterday.
- MR. GOETZ: I mean, it just -- and I'm just
- 18 curious. I -- I -- I wanted to know if you're looking
- 19 at a CMO because there was --
- MR. HYNES: It's not a CMO.
- MR. GOETZ: -- as to what -- as to whether
- you had to identify everything you showed to your
- 23 witnesses. There was that issue. And what it was
- resolved at, no, but everything he used for prep has
- to have been produced.


```
MR. HYNES: That was for 30(b).
 1
 2.
             MR. GOETZ: Okay. I -- I --
 3
              MR. HYNES: And that's for 30(b), not
 4
    everything -- but, listen, I'll -- I'll give it some
 5
     thought. This is what I've always done in
     depositions, and I've never had a problem with it.
6
 7
              Miles and I will talk about it at the
    break.
 8
9
              MR. GOETZ: Okay. Fair enough.
10
              MR. HYNES: Okay.
11
             MR. ROOF: Okay. So, my question --
12
             MR. HYNES: Do you want to ask the question
13
    again and I'll just say --
14
              MR. ROOF: Yeah.
              MR. HYNES: -- "same objection"?
15
16
    BY MR. ROOF:
17
18
19
20
21
22
23
24
25
```





















```
1
 2
 3
 4
 5
 6
 7
 8
 9
10
11
12
13
14
```


- Q. You've never seen or read 21 USC 823(e)?
- 16 A. I don't know that. This is 12 years ago.
- 17 I've basically been retired for six years. I can't
- 18 quote that code.
- Q. My question is: Have you seen that code
- 20 before?
- 21 A. I believe so.
- Q. Okay. As part of your job?
- 23 A. Or as a student.
- Q. You can't recall which one?
- 25 A. No.








































































```
1
 2
 3
 4
 5
 6
 7
 8
 9
10
11
12
              MR. HYNES: Can we would take a two-minute
    break? We've just been going for a while.
13
14
              MR. ROOF: Sure. Absolutely.
15
              THE VIDEOGRAPHER: Off the record at
16
     11:35 a.m.
17
              (There was a brief recess.)
18
              THE VIDEOGRAPHER: We are back on the record
19
    at 11:52 a.m.
20
    BY MR. ROOF:
21
22
23
24
25
```







```
Back up.
 1
              Have you seen Exhibit 111 before?
 2
 3
              MR. HYNES: Same objection as to documents
     reviewed during prep session.
 4
 5
          A. Yes.
 6
 7
 8
 9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
```













```
1
 2
 3
 5
 7
 8
 9
10
11
12
13
             MR. GOETZ: Do you want to break for lunch
14
   now?
15
             MR. HYNES: We might as well.
             THE VIDEOGRAPHER: We are off the record at
16
17
   12:03 p.m.
18
             (There was a luncheon break.)
              THE VIDEOGRAPHER: We are back on record at
19
20
    12:55 p.m.
21
    BY MR. GOETZ:
22
         Q. Mr. Millikan, my name is Dan Goetz. We met
23
  earlier.
24
             (CVS-Millikan-9 was marked for
25 identification.)
```


```
I'm going to hand you what has been marked as
 1
      Millikan Exhibit 9.
 2
               Do you recognize that document, sir?
 3
 4
          A. Yes.
 5
 6
 7
 8
 9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
```



































































```
1
 2
              MR. GOETZ: Off the record.
 3
              THE VIDEOGRAPHER: We're off the record at
 4
     1:27 p.m.
 5
              (There was a brief recess.)
              THE VIDEOGRAPHER: We're back on the record
 6
 7
    at 1:28 p.m.
 8
              (CVS-Millikan-48 was marked for
     identification.)
 9
10
    BY MR. GOETZ:
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
```




































```
1
 2
 3
 4
 5
 6
 7
 8
 9
10
11
12
13
14
15
16
17
              MR. GOETZ: Do you want to take a break or
18
    keep going?
              Mr. Millikan, would you like a short break or
19
20
    would you like to keep going?
21
              THE WITNESS: Whatever you want to do is fine
22
    with me.
23
              THE VIDEOGRAPHER: We are off record at
24
    1:46 p.m.
25
              (There was a brief recess.)
```


```
THE VIDEOGRAPHER: We are back on record at
 1
 2
     2:00 p.m.
 3
     BY MR. GOETZ:
 4
 5
 6
 7
 8
 9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
```































































```
1
 2.
              (CVS-Millikan-36 was marked for
     identification.)
 3
            I'm going to hand you Exhibit 36.
 4
              I just want to find out if these are the
 5
     instructions you're speaking about.
 6
 7
              Oh, sorry.
          Α.
 8
              These are not the instructions I'm referring
 9
     to.
10
          Q. Oh. Have you -- and you can object -- have
    you seen the instructions during your prep?
11
              MR. HYNES: Let me -- I'm going to object and
12
     tell him not to answer.
13
14
              We've produced the instructions if that's
15
    what you're getting at.
16
              MR. GOETZ: I -- I would like for you to
17
     identify. We --
18
              MR. HYNES: Okay.
19
              MR. GOETZ: I have no idea where they --
20
             MR. HYNES: Yeah, I can identify. It's not a
    problem. I can't do it, like, right now, but...
21
22
    BY MR. GOETZ:
23
24
25
```







```
1
 2
 3
 4
 5
 6
 7
 8
 9
10
11
12
13
14
             Mr. Millikan, you spent 35 years in a
          Q.
     distribution center distributing controlled drugs,
15
16
     correct?
              No.
17
          Α.
             How long?
18
          Q.
19
          Α.
             '95 to 2012.
20
          Q. Seventeen years?
21
          A. Yes.
22
          Q.
              Okay. You spent 17 years in a distribution
     center distributing controlled substances.
23
24
25
```








- 23 A. Near the southeast end of the building.
- Q. Where was the pharmacy office?
- A. Near the northeast end of the building.






































































































- 1 Review Report as potentially suspicious as identified
- by the computer algorithm model?
- 3 A. Yes.
- Q. When that order was on there, would you
- 5 automatically look at additional information that was
- 6 not shown on that Item Review Report?
- 7 A. No.
- 8 O. No.
- 9 So, there were oftentimes, and that's where
- 10 we started, and I apologize.
- 11 A. Oh, yes.
- Q. So when I said to you, Mr. Burtner, according
- 13 to those notes, looks at additional information not
- 14 shown on the Item Review Report two to three times,
- per hundred orders -- and we have been going through
- 16 those control studies to show you when he looks at an
- 17 IRR, how often he would look at additional due
- 18 diligence.
- 19 How often would you do additional due
- 20 diligence that was not reflected on the Item Review
- 21 Report for an order that was flagged? What
- 22 percentage?
- MR. HYNES: Object to form.
- Go ahead.
- A. I don't remember the percent, but it would


```
not be a large percent.
 1
          Q. And so, under five?
 2
              MR. HYNES: Objection to form.
 3
              Go ahead.
 4
 5
              Under 5 percent or under five --
              MR. GOETZ: Under 5 percent.
 6
 7
              THE WITNESS: Five percent.
 8
              MR. GOETZ: Under 5 percent.
              MR. HYNES: Objection to form.
 9
    BY MR. GOETZ:
10
          Q. Under 5 percent?
11
          A. I don't know, but, yes, probably.
12
13
14
15
16
17
18
19
20
21
22
23
24
25
```





















































```
1
 2.
 3
 5
 6
 7
 8
 9
10
11
              (CVS-Millikan-37 was marked for
12
     identification.)
13
              (CVS-Millikan-38 was marked for
    identification.)
14
              I'm going to show you what has been marked as
15
     Plaintiff's Exhibit 37 and Plaintiff's Exhibit 38.
16
17
              Here's 37 and 38.
18
              MR. HYNES: We're short a copy on 38.
19
              MR. GOETZ: I -- I apologize.
20
              Do you have a 38 for you?
21
              MR. HYNES: I do.
22
              MR. GOETZ: And does the witness have a 38?
23
              THE WITNESS: Yes.
24
              MR. GOETZ: Okay.
25
    BY MR. GOETZ:
```

```
1
          Q.
              Exhibit 37, do you see that?
 2.
          Α.
              Yes.
 3
 4
 5
 6
 7
 8
 9
10
11
12
          Q.
              And it's to Dan Deaton.
13
              Who's Dan Deaton?
14
          Α.
              He would have been a pharmacy supervisor
    probably at that time.
15
16
          Ο.
             And who's
17
          Α.
             The pharmacy manager at that time.
          Q. And who's Joseph Shohll?
18
          A. Was probably the logistics manager -- or I'm
19
20
     sorry -- the loss prevention manager.
21
22
23
24
25
```










```
1
2
3
4
5
6
7
8
9
```


- 10 Q. I will represent to you that from a period of
- 11 2-6 of 2013 to December 30th of 2013 -- strike that.
- Mr. Millikan, I'm handing you what has been
- marked as Exhibit 13. You're going to want to keep
- 14 that. It doesn't matter.
- 15 A. Oh.
- Q. That is a list of what says, Track One CVS
- 17 Store Information.
- Do you see that?
- 19 A. Yes.
- Q. All right. Do you understand that the first
- 21 opioid litigation case involves the County of
- 22 Cuyahoqa?
- A. I don't know that it's the first.
- Q. Okay. Do you understand that the County of
- 25 Cuyahoga, the City of Cleveland, the County of Summit,


```
and the City of Akron are joined together in one
 1
     lawsuit to be tried together?
 3
             Yes, I believe so.
          Α.
          Q. Okay. I will represent to you they are the
 4
 5
     first case that are scheduled to be tried.
 6
          A. Okay.
 7
              (CVS-Millikan-33 was marked for
     identification.)
 8
              These stores that you see on Exhibit 33,
 9
10
     they, according to what has been produced by CVS,
11
     represent those stores that are part of what we're
12
     calling track one, because that's the first case to be
13
     tried.
              Do you see up top: Track One CVS Store
14
     Information?
15
16
          A. Yes.
17
18
19
20
21
22
23
24
25
```






























```
1
 2
 3
 4
 5
 6
 7
 8
 9
10
11
12
13
14
              MR. GOETZ: Let's take a break.
15
16
              THE VIDEOGRAPHER: We are off record at
17
    4:36 p.m.
              (There was a brief recess.)
18
              THE VIDEOGRAPHER: We are back on the record
19
20
    at 4:49 p.m.
21
              MR. GOETZ: Mr. Millikan, I don't have any
    further questions for you, pending what Mr. Hynes asks
22
23
    you.
24
              THE WITNESS: Okay. Thank you.
25
              MR. GOETZ: And thank you for your time
```


```
today.
 1
               THE WITNESS: Thank you.
 2
 3
                             EXAMINATION
 4
    BY MR. HYNES:
 5
 6
 7
 8
 9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
```























```
1
 2
 3
 4
 5
 6
 7
              MR. GOETZ: That's all I have. Thank you,
 8
    sir.
 9
              THE WITNESS: Okay. Thank you.
10
11
              THE VIDEOGRAPHER: We are off the record at
    5:02 p.m.
12
13
14
15
16
17
18
19
20
21
22
23
24
25
```

```
1
     STATE OF KENTUCKY
                          ) SS
 2.
     COUNTY OF JEFFERSON
 3
          I, Kimberley Ann Keene, a notary public, within
     and for the State at Large, do hereby certify that the
 5
     foregoing deposition of
 6
                         GARY MILLIKAN
 7
    was taken before me at the time and place and for the
 8
    purpose in the caption stated; that the witness was
 9
     first duly sworn to tell the truth, the whole truth
10
     and nothing but the truth; that the deposition was
11
     taken before me stenographically and transcribed by
12
    me; that the foregoing is a full, true and complete
13
     transcript of the said deposition so given; that there
14
    was a request that the witness read and sign the
15
     transcript; that the appearances were as stated in the
16
     caption.
17
          I further certify that I am neither counsel or of
18
    kin to any of the parties to this action, and am in no
19
     way interested in the outcome of said action.
20
          Witness my signature this 14th day of January,
21
             My Commission Expires on September 16, 2020.
22
23
          Kimberley Ann Keene
24
          Registered Professional Reporter
25
```

Case: 1:17-md-02804-DAP Doc.#: 1965-82 Filed: 07/23/19 264 of 265 PageID.#: 169000 Highly Confidential Ey Review

1		
		ERRATA
2		
3	PAGE LINE	CHANGE
4		
5	REASON:	
6		
7	REASON:	
8		
9	REASON:	
	REASON:	
12		
13	REASON:	
14		
15	REASON:	
16		
17	REASON:	
18		
19	REASON:	
20		
21	REASON:	
22		
23	REASON:	
	——— ———— REZSON•	
2425	REASON:	

Case: 1:17-md-02804-DAP Doc.#: 1965-82 Filed: 07/23/19 265 of 265 PageID #: 169001 Review

ACKNOWLEDGMENT OF DEPONENT
I,, do
hereby certify that I have read the
foregoing pages, and that the same
is a correct transcription of the answers
given by me to the questions therein
propounded, except for the corrections or
changes in form or substance, if any,
noted in the attached Errata Sheet.
GARY MILLIKAN DATE
Subscribed and sworn
to before me this
, day of, 20
My commission expires:
Notary Public